Wellington Management Group LLP Decreases Stake in Qiagen N.V. $QGEN

Wellington Management Group LLP cut its stake in shares of Qiagen N.V. (NYSE:QGEN) by 13.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 12,406,763 shares of the company’s stock after selling 1,957,540 shares during the quarter. Wellington Management Group LLP owned about 0.06% of Qiagen worth $484,208,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in QGEN. Vanguard Group Inc. lifted its stake in shares of Qiagen by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 9,542,944 shares of the company’s stock valued at $433,871,000 after purchasing an additional 118,135 shares during the period. Price T Rowe Associates Inc. MD grew its position in Qiagen by 12.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock worth $379,072,000 after buying an additional 906,589 shares during the period. Deutsche Bank AG grew its position in Qiagen by 9.7% during the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock worth $355,614,000 after buying an additional 697,342 shares during the period. Amundi increased its holdings in Qiagen by 12.4% in the first quarter. Amundi now owns 4,757,681 shares of the company’s stock valued at $190,498,000 after buying an additional 524,959 shares in the last quarter. Finally, Boston Partners purchased a new position in Qiagen in the third quarter valued at about $179,450,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Stock Down 1.5%

Shares of NYSE QGEN opened at $43.08 on Friday. Qiagen N.V. has a 12-month low of $32.53 and a 12-month high of $57.81. The company has a market capitalization of $8.88 billion, a PE ratio of 22.07, a price-to-earnings-growth ratio of 4.29 and a beta of 0.63. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31. The firm’s 50-day moving average is $41.37 and its two-hundred day moving average is $40.66.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The business had revenue of $535.04 million during the quarter, compared to analysts’ expectations of $527.50 million. During the same period last year, the company posted $0.60 EPS. The company’s revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. Equities analysts anticipate that Qiagen N.V. will post 2.43 EPS for the current fiscal year.

Key Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: The FDA cleared Qiagen’s QIAstat-Dx BCID GPF Plus AMR Panel, giving the company its first entry into the U.S. bloodstream-infection testing market. The automated test detects 20 bacterial and fungal targets plus 10 genetic antimicrobial-resistance markers and runs on a platform with more than 5,200 placements globally, creating potential for added instrument and consumables revenue. Could Qiagen Stock Win as Its FDA Clearance Opens a New Diagnostics Market?
• Positive Sentiment: Qiagen launched QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic-acid extraction. The product builds on a QIAsymphony installed base of more than 3,300 systems and could support recurring demand for Qiagen’s laboratory consumables and assays. QIAGEN Launches QIAsymphony Connect
• Neutral Sentiment: Zacks Research made small, mixed adjustments to its forecasts. It maintained a “Hold” rating and kept fiscal 2026 EPS at $2.43, while raising fiscal 2028 EPS to $2.91 from $2.88. However, fiscal 2027 EPS was lowered to $2.60 from $2.63, suggesting limited near-term earnings momentum. Qiagen analyst estimates
• Negative Sentiment: A Delaware jury found Parse Biosciences, which Qiagen acquired, willfully infringed three patents exclusively licensed to Scale Biosciences, a 10x Genomics subsidiary. Potential damages, royalties, or other remedies could increase costs and create uncertainty around Parse’s business, although the financial impact was not disclosed. 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on QGEN shares. JPMorgan Chase & Co. lifted their price target on shares of Qiagen from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Qiagen in a research note on Thursday, August 6th. Kepler Capital Markets set a $38.60 price objective on Qiagen and gave the stock a “hold” rating in a report on Thursday, June 25th. Citigroup reiterated a “neutral” rating and set a $45.00 target price (up from $38.00) on shares of Qiagen in a research report on Monday, August 10th. Finally, Berenberg Bank set a $45.50 target price on Qiagen and gave the company a “hold” rating in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $43.93.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.